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ABSTRACT
Background
Evidence suggests that variations in fasting glucose and insulin amongst those without frank
type 2 diabetes mellitus are important determinants of cardiovascular disease. However, the
relative importance of variations in fasting insulin, glucose, and glycated haemoglobin as risk
factors for cardiovascular disease in women without diabetes is unclear. Our aim was to
determine the independent associations of fasting insulin, glucose, and glycated haemoglobin
with coronary heart disease and stroke in older women.
Methods and Findings
We undertook a prospective cohort study of 3,246 British women aged 60–79 y, all of whom
were free of baseline coronary heart disease, stroke, and diabetes, and all of whom had fasting
glucose levels below 7 mmol/l. Fasting insulin and homeostasis model assessment for insulin
sensitivity (HOMA-S) were linearly associated with a combined outcome of coronary heart
disease or stroke (n¼ 219 events), but there was no association of fasting glucose or glycated
haemoglobin with these outcomes. Results were similar for coronary heart disease and stroke
as separate outcomes. The age, life-course socioeconomic position, smoking, and physical
activity adjusted hazard ratio for a combined outcome of incident coronary heart disease or
stroke per one standard deviation of fasting insulin was 1.14 (95% CI 1.02–1.33). Additional
adjustment for other components of metabolic syndrome, low-density lipoprotein cholesterol,
fasting glucose, and glycated haemoglobin had little effect on this result.
Conclusions
Our findings suggest that in women in the 60–79 y age range, insulin resistance, rather than
insulin secretion or chronic hyperglycaemia, is a more important risk factor for coronary heart
disease and stroke. Below currently used thresholds of fasting glucose for defining diabetes,
neither fasting glucose nor glycated haemoglobin are associated with cardiovascular disease.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org August 2007 | Volume 4 | Issue 8 | e263 1396
PLoS MEDICINEIntroduction
Diabetes is known to be one of the most potent risk factors
for coronary heart disease (CHD) and stroke in women and
men [1–3], but the mechanisms for these associations are
unclear. Insulin resistance is a precursor to glucose intoler-
ance and type 2 diabetes mellitus. The progression from
insulin resistance to impaired glucose tolerance (character-
ised predominantly by postprandial hyperglycaemia) occurs
as a result of early pancreatic b-cell dysfunction [4,5]. With
worsening b-cell dysfunction this leads to overt type 2
diabetes [4,5]. Once diabetes has occurred there is no further
marked deterioration in insulin resistance; instead, poor
insulin secretion (b-cell dysfunction) becomes the main
pathological process [6,7]. Thus, the association of type 2
diabetes with cardiovascular disease may reﬂect determinants
and consequences (including hyperinsulinaemia) of insulin
resistance, or determinants and consequences (including
hyperglycaemia) of reduced insulin secretion, or a combina-
tion of these processes. Exploring the relative associations of
hyperinsulinaemia and hyperglycaemia with cardiovascular
disease in individuals without type 2 diabetes should provide
insights into the mechanisms linking type 2 diabetes to
increased cardiovascular disease risk.
Several studies have demonstrated that different measures
of glucose or insulin metabolism or homeostasis are related
to future CHD or stroke risk in individuals without diabetes
[8–14], but few have compared the magnitude and independ-
ence of associations with markers that reﬂect insulin
resistance and those that reﬂect reduced insulin secretion
within the same study. It is therefore difﬁcult to determine
from current research whether the association between
diabetes and cardiovascular disease is primarily driven by
insulin resistance–related factors, insulin secretion–related
factors, or both. Differences in associations across different
studies are difﬁcult to interpret since these might reﬂect
different study protocols.
Further, few studies have explored these associations in
women or in older individuals. For example, in two meta-
analyses of the associations of glucose (fasting or post-load)
with CHD or cardiovascular disease (including CHD, stroke,
and other vascular outcomes) in individuals without diabetes,
one reported that the vast majority of studies were of middle-
aged men, with only 4% of the participants (2% of events)
contributing to the pooled estimates being female [10]. In the
second (more recent) meta-analysis this proportion had
increased, but remained low with just 17% of participants
(15% of events) being female [8]. In the Asia Paciﬁc
Collaboration (a meta-analysis of cohort studies from the
Asia Paciﬁc region), which included studies of the association
of fasting glucose with CHD and stroke irrespective of
whether participants with diabetes were excluded or not,
43% of the participants were female but less than one-third
of the CHD events were in females [15]. In all three of these
studies the mean age at baseline assessment of study
participants was under 60 y in over 90% of the included
studies; in the Asia Paciﬁc Collaboration the mean age at
baseline was particularly young at just 47 y across all studies.
Similarly, in a recent meta-analysis of the association of
insulin with cardiovascular disease just 11% of the cases were
female and the mean age of participants was less than 60 y in
all of the included studies [9].
There are several reasons why it is important to establish
these associations in older women. CHD and stroke occur
most commonly in those aged 60 y or over, and together
occur equally in women and men. One cannot assume that
associations of glucose and insulin metabolism with cardio-
vascular disease will be similar in women and men. Both the
increased absolute and relative risk of CHD in individuals
with diabetes is greater for women than men [16], suggesting
that there are gender differences in the mechanism under-
lying this association.
The aim of this study was to examine the associations of
fasting insulin, glucose, and glycated haemoglobin (HbA1c)
with CHD and stroke in older women without diabetes
(deﬁned as no clinical diagnosis and a fasting glucose less
than 7 mmol/l). This work will add to current research by
directly comparing these markers of insulin resistance
(fasting insulin) and insulin secretion (fasting glucose and
HbA1c) within the same study population and by exploring
these associations in older women.
Methods
Participants
Full details of the selection of participants and measure-
ments have been previously reported [17]. Women aged 60–
79 y were randomly selected from general practitioner lists in
23 British towns. A total of 4,286 women (60% of those
invited) participated, and baseline data (self-completed
questionnaire, research nurse interview, physical examina-
tion, and medical record review) were collected between
April 1999 and March 2001. Over 99% of the participants
were described by the examining nurse as ‘‘white,’’ with this
ethnic distribution and the social class distribution of the
participants in this cohort matching that of all British women
of the same age based on census data from 1991 and 2001
[17]. For the present analyses we excluded all women with a
medical diagnosis of diabetes or who had a fasting glucose of
  7.0 mmol/l (n ¼ 377), and all women who had a medical
diagnosis of CHD or stroke (an additional n¼663), which left
3,246 women who fulﬁlled the eligibility criteria for the
current study. These women have been followed up over a
median of 4.6 y, to December 2004, by a detailed review of
their medical records, conducted every 2 y, to identify
nonfatal CVD events and, by ﬂagging with the National
Health Service Central Register (NHSCR), to obtain mortality
data. There was no loss to follow-up for this linkage to vital
status and medical records.
Measurements
Venous blood samples were taken after a minimum 8 h fast
(veriﬁed by the research nurse). Women who had blood
samples taken in the morning had fasted overnight (i.e., for
10–12 h), whereas those who had samples taken later in the
day had fasted for shorter periods (8–9 h) on average. There
were no differences in any of the associations examined here
when we stratiﬁed the sample according to whether the
women had fasted overnight or not. Adjustment of our
ﬁndings for time at which blood samples were taken did not
affect any results.
Plasma glucose was measured by a glucose oxidase Trinder
method [18] using a Hitachi Modular analyser. Serum insulin
was measured using an ELISA assay that does not cross react
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blood using the Drew Hb Gold instrument, which is a High
Performance Liquid Chromatography (http://www.
drew-scientiﬁc.com/). We used the HOMA calculator (Oxford
Centre for Diabetes, Endocrinology & Metabolism, Diabetes
Trials Unit, http://www.dtu.ox.ac.uk/) to compute a measure of
insulin sensitivity (HOMA-S) using fasting glucose and insulin
[20]. This method of calculating HOMA uses a corrected
formula that is believed to be a more accurate reﬂection of
insulin sensitivity than the older method [20]. For HOMA-S
higher values indicate less insulin resistance and are
potentially less harmful to health. By contrast higher levels
of fasting insulin are related to greater insulin resistance and
are potentially harmful to cardiovascular health.
Incident CHD and stroke were the study outcomes.
Incident cases of CHD (in those without baseline CHD) were
deﬁned as any of CHD death (ICD-10 codes I20-I25, I51.6) or
a nonfatal myocardial infarction, angina diagnosis or
coronary artery bypass, or angioplasty identiﬁed in the
follow-up medical record reviews. Incident cases of stroke
(in those without baseline stroke) were deﬁned as either
stroke death (ICD-10 codes I60-I69, G45) or occurrence of a
nonfatal stroke identiﬁed in the follow-up medical record
reviews.
We examined whether associations were independent of
potential confounding factors (life course socioeconomic
position [SEP], smoking, and physical activity) and whether
they were independent of other components of the metabolic
syndrome (high density lipoprotein cholesterol, triglyceride
levels, systolic blood pressure, body mass index, and waist-to-
hip circumference), which we did not consider to be
confounding factors but which may provide insights into
the mechanisms by determining whether any associations
were mediated by other these relative risk factors.
High-density lipoprotein cholesterol (HDL-c) and trigly-
ceride levels were measured, on fasting venous blood samples,
using a Hitachi 747 automated analyser and reagents supplied
by Roche Diagnostics (http://www.roche.com/div_diag.htm).
Low-density lipoprotein cholesterol (LDL-c) was calculated
using the Friedwald equation (LDL-c ¼ total cholesterol  
[HDL-c þ triglycerides 3 0.45]) [21]. Standard examination
procedures were used to assess blood pressure, height, weight,
and waist and hip circumference as previously described [17].
Data on childhood and adulthood SEP were obtained from
baseline questionnaires and combined into a life-course SEP
score, as previously described [21], which indicated the
number of adverse life-course SEP from 0/1 through to 9/10.
Information on smoking (categorised as never, past, and
current) and physical activity (a frequency and duration
questionnaire used to estimate hours spent in moderate or
vigorous activity per week) was obtained from the baseline
questionnaires and research nurse interviews.
Study Ethics
Informed consent was obtained from the women to
examine their medical records and link them to the NHSCR.
Both local and multicentre ethics committees’ approvals were
obtained for the study.
Statistical Analyses
Fasting insulin, glucose, HOMA-S, and triglyceride levels all
had positively skewed distributions and therefore log-trans-
formed values were used in the estimation of correlation
coefﬁcients and in the regression models. Pairwise Pearson
correlation coefﬁcients were estimated between fasting
glucose, insulin, HOMA-S, HbA1c, and other continuous
variables. In this population most of the strokes are likely to
be ischaemic and therefore have a similar aetiology to CHD
[23]. However, for all models we examined associations with
CHD only, stroke only, and a combined outcome of CHD and
stroke. We examined whether there was any evidence of
heterogeneity between associations with these three different
outcomes using a z-statistic. There was no evidence of
heterogeneity for the different outcomes with any of the
exposures in any models (all p-values .0.7).
Cox proportional hazard models were used to examine the
prospective associations of both exposures and potential
confounding factors with incident CHD and stroke (fatal and
nonfatal). In the Cox proportional hazards models, the
participant’s age was the time axis, and risk was assessed
from the date of baseline examination for each woman.
Contributions to risk were censored at the date of ﬁrst
outcome event of interest, death from any other cause, or the
end of the follow-up period (31 December 2004) for those
who remained alive and free of CHD or stroke. In order to
compare the magnitudes of the associations of each exposure
(fasting glucose, insulin, and HbA1c) with the outcomes, we
estimated effects (hazard ratios) per standard deviation (SD)
of each exposure, using the SD of the log-transformed values
of fasting insulin and glucose. Despite being censored at its
upper end (7 mmol/l), the distribution of log-transformed
values of fasting glucose in those women included in our
analyses was approximately normal.
The nature of associations (linear and nonlinear) were
examined in two ways. First, we examined associations of
outcomes with ﬁfths of the distribution of each exposure, and
computed likelihood ratio tests to compare a model with
these ﬁve categories entered as four indicator (dummy)
variables (nonlinear model) to a model with the ﬁve
categories entered as one variable—an ordered categorical
variable (linear model). Second, we tested for statistical
evidence of quadratic or higher power curvilinear associa-
tions by using each exposure as a continuous variable (per SD
change) and computing a likelihood ratio test to compare
each of a series of models that all contained the ﬁrst-order
term and additionally second-, third-, or fourth-order terms,
with a model including only the ﬁrst-order term. The
advantage of the ﬁrst approach is that it examines a general
nonlinear association without specifying the particular form
of this nonlinear association. The second approach tests
speciﬁc curvilinear associations and produces a more speciﬁc
description of any nonlinear association.
For several of the variables included in the analyses there
were small amounts of missing data, varying from 0% to 13%
for any individual variable (see Tables 1 and 2). Missing data
resulted from a number of different reasons, including
participant’s nonresponse to speciﬁc questions, failure of
participant to complete parts of the physical examination,
failure of participant to provide a blood sample or to provide
sufﬁcient blood for all of the tests we proposed doing in this
cohort study (we attempted to obtain 20 ml of blood from all
participants), and inability of the laboratory to complete a
particular assay on a particular sample.
For the Cox proportional hazards models we used a
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in any analyses and the log of survival time for Cox models, to
impute a distribution of missing values for those variables
with some missing data with switching regression [24]. We
carried out 20 cycles of regression switching, and generated
ten imputation datasets. This approach creates a number of
copies of the data (in this case we generated ten copies) each
of which has values that are missing imputed with an
appropriate level of randomness using chained equations
[24]. The results are obtained by averaging across the results
from each of these datasets using Rubin’s rules, and the
procedure takes account of uncertainty in the imputation as
well as uncertainty due to random variation (as undertaken in
all multivariable analyses) [24]. This method assumes that data
are either ‘‘missing completely at random’’ or are ‘‘missing at
random,’’ but are not ‘‘missing not at random’’ (i.e., it assumes
that the probability of missing data does not depend on the
outcome of interest). Although it is never possible to test this
assumption, in this particular case it seems unlikely that the
probability that a woman had missing information on her
fasting values of glucose, insulin, or HbA1c, or the probability
that she had missing data on some of the other covariables
that were missing, was dependent upon her risk of experi-
encing a future CHD or stroke event. To further explore this
possibility we also undertook all analyses on the complete
dataset subsample. The results from the complete data subset
analyses (n ¼ 2,154 [66% of the 3,246 women included in the
study]) were essentially the same as those obtained by
combining results from the multiple imputation datasets,
but were less precisely estimated. In this paper we present
results from the multivariate multiple imputation models.
Complete dataset subsample analyses are available in Table
S1. All analyses were conducted using Stata version 9.2 (Stata,
http://www.stata.com/).
Results
Tables 1 and 2 show the baseline characteristics of the 3,246
women included in our analyses. Table 3 shows the pairwise
correlations between continuously measured traits. There
was near perfect inverse correlation between fasting insulin
and HOMA-S and all associations in the Cox models were of
the same magnitude (though inverse for HOMA-S) whichever
of fasting insulin or HOMA-S was used, and therefore only
associations with fasting insulin are presented. There were
modest correlations between fasting glucose, insulin and
HbA1c, and also modest correlations between each of these
and most other continuous traits. The two exceptions were
systolic blood pressure and LDL-c, which had only weak or no
correlations with other variables. Waist circumference was
strongly correlated with waist-to-hip ratio, and the magni-
tude of correlations between waist circumference with other
metabolic and vascular measures were very similar to those
presented in Table 3 for waist-to-hip ratio (unpublished
data).
Of the 3,246 women included in the analyses, 174
Table 1. Baseline Characteristics of Women Aged 60–79 Years
and Free of Diabetes, CHD, and Stroke: Continuous Variables
Variable Mean (Variance) n (%) with
Missing Data
Age, y 68.6 (5.5)
a 0
HbA1c, % 4.90 (0.83)
a 421 (13)
Fasting glucose, mmol/l 5.88 (5.85–5.92)
b 363 (11)
Fasting insulin, lU/l 6.75 (6.60–6.90)
b 330 (10)
HOMA-S, % 100.1 (98.2–102.0)
b 373 (11)
Triglycerides, mmol/l 1.64 (1.62–1.67)
b 344 (11)
HDL-c, mmol/l 1.67 (0.45)
a 350 (11)
LDL-c, mmol/l 4.20 (1.08)
a 344 (11)
Body mass index, kg/m
2 27.4 (4.9)
a 254 (8)
Waist-to-hip ratio 0.816 (0.068)
a 266 (8)
Waist, mm 859.5 (119.0)
a 266 (8)
Systolic blood pressure, mm Hg 147.5 (24.9)
a 249 (8)
Total n ¼ 3,246.
aArithmetric mean with SD.
bGeometric mean and 95% confidence interval.
doi:10.1371/journal.pmed.0040263.t001
Table 2. Baseline Characteristics of Women Aged 60–79 Years and Free of Diabetes, CHD, and Stroke: Categorical Variables
Variable Subcategory Number (%) n (%) with Missing Data
Smoking Never 1,831 (56.7) 14 (0.4)
Past 1,022 (31.6)
Current 379 (11.7)
Moderate or vigorous physical activity, h/wk ,2 1,932 (61.9) 125 (4)
2–2.99 343 (11.0)
 3 846 (27.1)
Childhood indicators of SEP Manual social class 2,435 (75.0) 0
No bathroom in childhood home 1,183 (38.2) 149 (4.5)
No hot water in childhood home 1,071 (34.8) 165 (5)
Shared a bedroom as a child 1,597 (51.8) 165 (5)
Family had no access to a car as a child 2,473 (81.6) 215 (7)
Left full-time education before age 15 y 1,008 (33.3) 220 (7)
Adult indicators of SEP Manual social class 1,624 (50.0) 0
No car access as an adult 838 (27.0) 139 (4)
Living in public (council) housing 396 (11.9) 140 (4)
Only retirement income will be state pension 790 (27.0) 321 (10)
Total n ¼ 3,246.
doi:10.1371/journal.pmed.0040263.t002
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per 1,000 women-years (95% CI 10.6 to 14.2); 52 experienced
an incident case of stroke, giving a rate of 3.6 per 1,000
woman-years (95% CI 2.7 to 4.7); and 219 experienced an
incident case of either CHD or stroke giving a rate of 15.5 per
1,000 woman-years (95% CI 13.6 to 17.7). Note the total with
either CHD or stroke (219) is smaller than the sum of those
experiencing a CHD event (174) or a stroke (52), because
seven women experienced both a CHD event and a stroke
during the follow-up period.
Table 4 shows the age-adjusted (age being the time scale in
the proportional hazards models) associations of potential
confounding factors with CHD or stroke risk. Most estab-
lished risk factors were associated with CHD or stroke in this
cohort: low socioeconomic position, smoking, physical
inactivity, higher waist-to-hip ratios, LDL-c, triglycerides,
and systolic blood pressure and lower HDL-c levels. Body
mass index was not associated with CHD or stroke in this
cohort.
Table 5 shows the multivariable associations of fasting
glucose, insulin, and HbA1c with incident CHD and stroke. In
these analyses only fasting insulin was associated with
incident outcomes. The association of fasting insulin with
incident outcomes was linear across the distribution with no
statistical evidence from models with indicator variables or
from higher-order curvilinear variables of nonlinear associ-
ations (all p-values .0.2). There was no evidence of linear or
nonlinear associations of either fasting glucose or HbA1c
with incident CHD or stroke (all p-values .0.3). The
association of fasting insulin with incident outcomes attenu-
ated with adjustment for potential confounders (model 2),
with little further attenuation upon additional adjustment for
other components of metabolic syndrome and LDL-c (model
3) or for fasting glucose and HbA1c (model 4). There was
weak statistical evidence that the association of fasting insulin
with incident CHD or stroke was greater than the association
of either fasting glucose or HbA1c with this outcome (both p
¼0.09). When we excluded the ﬁrst year of follow-up in these
analyses to minimise the possibility of reverse causality, the
associations with CHD (n¼120 cases with ﬁrst year excluded)
and combined CHD and stroke (n ¼ 157) were the essentially
the same as those presented in Table 5.
We stratiﬁed the women into two age groups at baseline
(60–69 y or 70–79 y) in order to determine whether any
associations differed by age. Correlation coefﬁcients between
continuous variables were similar in each age group and
there was no evidence that the associations of any of the
exposures with incident outcomes differed by age group. All
point estimates were similar for the two age groups, and p-
values for interaction with age group were   0.7.
Table 4. Age-Adjusted Associations of Covariable Factors with
CHD or Stroke
Covariable Category of
Exposure
Hazard Ratio (95% CI)
for Experiencing
Either CHD or Stroke
Age Per SD (1 SD ¼ 5.5) 2.55 (1.50–4.22)
Life-course SEP score
a Per one additional
adverse characteristic
1.10 (1.05–1.16)
Smoking Never 1
Past 1.31 (1.01–1.77)
Current 2.94 (2.13–4.06)
Physical activity
(h/wk moderate
to vigorous activity)
,21
 2 1.73 (1.27–2.35)
BMI Per SD (1SD ¼ 4.9) 1.04 (0.92–1.19)
Waist-to-hip ratio Per SD (1SD ¼ 0.068) 1.15 (0.98–1.36)
LDL-c Per SD (1SD ¼ 1.08) 1.14 (1.00–1.30)
HDL-c Per SD (1SD ¼ 0.46) 0.84 (0.69–1.00)
Triglycerides Per SD (1SD ¼ 0.45) 1.11 (0.97–1.30)
Systolic blood pressure Per SD (1SD ¼ 24.9) 1.15 (1.01–1.32)
Total n ¼ 3,246 (with multivariate multiple imputation datasets). All estimates are age
adjusted except for age itself.
aThe life-course SEP is a summation of ten indicators of adverse SEP from across the life-
course; a higher score indicates a greater number of adverse socioeconomic position
indicators.
doi:10.1371/journal.pmed.0040263.t004
Table 3. Pairwise Correlations between Continuous Variables in Women Aged 60–79 Years and without Diabetes
Variables FG FI HOMA-S HbA1c LDL-c HDL-c TG BMI WHR SBP
FG 1 — — — — — — — — —
FI 0.25 1 — — — — — — — —
HOMA-S  0.30  1.00 1 — — — — — — —
HbA1c 0.21 0.16  0.17 1 — — — — — —
LDL-c  0.04
a  0.02
b  0.02
b  0.04
c 1— — — ——
HDL-c  0.07  0.28 0.28  0.05  0.27 1 — — — —
TG 0.09 0.37  0.37 0.13 0.36  0.50 1 — — —
BMI 0.10 0.44  0.44 0.12 0.16  0.26 0.25 1 — —
WHR 0.10 0.33  0.34 0.10 0.20  0.22 0.30 0.35 1 —
SBP 0.09 0.05
a  0.05
a 0.00
d 0.04
c 0.00
d 0.13 0.05
a 0.11 1
Total n ;2,900 (varies slightly for different pairwise comparisons).
All p-values , 0.001 except:
ap ¼ 0.01.
bp ¼ 0.34.
cp ¼ 0.02.
dp ¼ 0.99.
FG, fasting glucose; FI, fasting insulin; TG, triglycerides; BMI, body mass index; WHR, waist to hip ratio; SBP, systolic blood pressure.
doi:10.1371/journal.pmed.0040263.t003
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In this general population study of older British women
who were free from clinically diagnosed diabetes and who had
fasting glucose levels of less than 7 mmol/l and no clinical
evidence of CHD or stroke at baseline, we found only modest
correlations between fasting insulin, fasting glucose, and
HbA1c levels. Only fasting insulin, but not glucose or HbA1c,
was associated with incident CHD and stroke. This associa-
tion remained with adjustment for potential confounding
factors, other components of the metabolic syndrome, LDL-c,
fasting glucose, and HbA1c. Few previous studies have
directly compared the associations of fasting glucose, insulin,
and glycated haemoglobin within the same study population,
though several have compared each of these components
singly within different studies.
Numerous studies have examined the association of fasting
or post-load blood glucose levels in the nondiabetic range
with CHD and/or stroke risk, but deﬁnitions and results have
been inconsistent and few studies have examined associa-
tions in older women, a group at high risk for these
outcomes. A meta-analysis of studies published up to 1996
(only 6% of participants were female and just 2% of events
occurred in females) found that the association was
consistent with the null hypothesis when the analyses were
limited to categories with values lower than 7.8 mmol/l,
though overall the authors concluded there was an expo-
nential association between fasting glucose and CHD [10]. In
a more recent meta-analysis (17% of participants were
females, who accounted for 15% of events) the pooled
relative risk for studies that strictly excluded individuals with
baseline diabetes (diagnosed or with fasting glucose .7.0
mmol/l) was 1.26 (95% CI 1.11–1.43) comparing the highest
to lowest glucose category and in studies that did not exclude
individuals with high fasting glucose levels it was 1.48 (95%
CI 1.25–1.75), with weak evidence that these two estimates
differed from each other (p ¼ 0.14) [8]. This recent meta-
analysis also found a threshold effect of the association
between fasting glucose and all cardiovascular diseases with
no association in levels below 5.6 mmol/l [8]. Consistent with
this latter meta-analysis in the Asia Paciﬁc Collaboration,
which included more females than previous meta-analyses
(43% of participants, and ; 30% of CHD events and 50% of
stroke events) there was a linear association of fasting glucose
down to levels of 4.9 mmol/l for either CHD or stroke in both
females and males [15]. However, participants in that study
were considerably younger than in the present study (mean
age 47 y) and there was some evidence that the association of
fasting glucose with both CHD and stroke was weaker in
those less than 60 y of age than in those older than 60 y [15].
For most of the studies included in the meta-analysis those
with diabetes at baseline were not excluded, though existence
of diabetes at baseline did not appear to be a major source of
heterogeneity [15]. Taken together with our ﬁndings, these
results suggest that fasting glucose may not be associated
with future CHD or stroke risk across the range of normal
glucose values. Our results suggest that in women aged 60–79
y with levels below the threshold of fasting glucose currently
used to indicate diabetes (7 mmol/l), there appears to be no
association of fasting glucose with CHD and stroke, though
for the latter outcome, in particular, further larger studies
are required.
Our ﬁnding that HbA1c is not associated with incident
outcomes is consistent with ﬁndings from the Atherosclerosis
Risk in Communities cohort, which found no overall linear
association between HbA1c and incident CHD in nondiabetic
individuals, though HbA1c was positively associated with
incident CHD in those with a baseline value of HbA1c of
greater than 4.6% in that study [25]. By contrast, the
European Prospective Investigation into Cancer-Norfolk
study found positive linear associations across the HbA1c
distribution with incident cardiovascular disease (CHD,
stroke, and other vascular and cardiac outcomes) and CHD
events in women and men without diabetes [13]. In the main
analyses in that study, individuals with baseline CVD were
Table 5. Multivariable Association of Fasting Glucose, Insulin, and Glycated Haemoglobin with Incident CHD and Stroke in Women
Aged 60–79 Years and Free of Diabetes and Cardiovascular Disease at Baseline
Outcome Category Model Per 1 SD Fasting Insulin Per 1 SD Fasting Glucose Per 1 SD Glycated Haemoglobin
Incident CHD (n ¼ 174) Model 1 1.18 (1.04–1.36) 1.09 (0.95–1.25) 1.08 (0.95–1.23)
Model 2 1.15 (1.02–1.32) 1.07 (0.94–1.24) 1.05 (0.92–1.20)
Model 3 1.15 (1.02–1.32) 1.06 (0.91–1.23) 1.04 (0.90–1.20)
Model 4 1.14 (1.00–1.32) 1.05 (0.90–1.23) 1.02 (0.88–1.19)
Incident stroke (n ¼ 52) Model 1 1.18 (0.89–1.56) 1.14 (0.88–1.47) 1.05 (0.81–1.38)
Model 2 1.13 (0.84–1.48) 1.11 (0.86–1.43) 1.00 (0.77–1.30)
Model 3 1.16 (0.83–1.59) 1.11 (0.86–1.43) 1.02 (0.79–1.33)
Model 4 1.14 (0.82–1.58) 1.10 (0.82–1.47) 1.00 (0.76–1.32)
Incident CHD or stroke (n ¼ 219) Model 1 1.18 (1.03–1.35) 1.09 (0.94–1.25) 1.05 (0.91–1.22)
Model 2 1.14 (1.01–1.33) 1.07 (0.93–1.22) 1.02 (0.88–1.18)
Model 3 1.14 (1.01–1.33) 1.06 (0.92–1.23) 1.02 (0.87–1.18)
Model 4 1.13 (0.98–1.32) 1.05 (0.90–1.23) 1.00 (0.86–1.17)
Data are presented as hazard ratio (95% CI). Total n ¼ 3,246 (with multivariate multiple imputation datasets).
Model 1: Adjusted for age.
Model 2: As model 1 plus confounder adjusted (life course socioeconomic position, smoking and physical activity).
Model 3: As model 2 plus adjusted for other components of the metabolic syndrome (body mass index, waist-to-hip ratio, high density lipoprotein cholesterol, triglyceride levels, and
systolic blood pressure) and LDL-c. Note: When waist circumference was used instead of waist-to-hip ratio none of the results changed from those presented.
Model 4: As model 3 plus mutual adjustment for other exposures (fasting glucose, insulin, and HbA1c).
doi:10.1371/journal.pmed.0040263.t005
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positive association in that study may, therefore, be exagger-
ated by reverse causality. In a prospective case-control study
nested within the Women’s Health Study there was a positive
association between HbA1c and incident CHD in women
without diabetes in unadjusted analyses, but this attenuated
completely to the null with adjustment for other CHD risk
factor [26]. Thus, the overall evidence, while scant, does not
suggest a strong association between HbA1c and CHD or all
cardiovascular diseases in nondiabetic women.
Our ﬁndings of a positive linear association between
fasting insulin and CHD and stroke events is consistent with
ﬁndings from the Atherosclerosis Risk in Communities study,
in which there was a positive linear association with CHD
events that remained after adjustment for other CHD risk
factors amongst women, but not amongst men [27]. A
metaregression analysis of 17 prospective studies, primarily
conducted in men and younger age groups than the current
study, found a pooled relative risk of CHD per 50 pmol/l of
insulin of 1.18 (95% CI 1.08–1.29) [9], which is consistent with
our fully adjusted association with CHD (our results equate to
1.13 [95% CI 1.01–1.27] per 50 pmol/l of insulin). Overall the
evidence suggests a modest positive association between
fasting insulin and CHD events in women and men. Fasting
insulin may exert its effect on cardiovascular risk via a direct
impact on endothelial function [28,29].
Study Limitations
In common with most epidemiological studies, we had just
one baseline measurement of each exposure variable, and
therefore our effect estimates may underestimate the true
association if regression dilution bias is taken into account.
Whilst oral glucose tolerance tests and eugylcaemic clamp
studies are the gold standard for determining hyperglycaemia
and insulin resistance they are difﬁcult to conduct in large
scale epidemiological studies [30]. Further, in routine clinical
practice, assays of fasting blood samples to determine CHD
risk are more feasible than these more complex methods. For
women who were examined in the afternoon their fasting
time (8–9 h) was shorter than the recommended 12 h.
However, in stratiﬁed analyses all results were the same in
those with an overnight fast and those who had fasted for a
shorter time. Amongst participants in this study, consistent
with other studies, mean fasting glucose and insulin levels fell
slightly during the morning and then remained stable across
time in the afternoon [31]. However, adjustment for time of
day of blood sampling had no effect on any results presented
here. We had too few incident cases of stroke for precise
analyses and are unable to determine whether these were
ischemic or haemorrhagic stroke. We found no statistical
evidence of heterogeneity in effect between results from our
three outcomes (CHD alone, stroke alone, or CHD and stroke
combined), but would have limited power in this study to ﬁnd
heterogeneity if it existed because of the small number of
stroke cases. In this population it is likely that the majority of
strokes will be ischemic and as such have a similar
pathophysiology to CHD [23,32], which justiﬁes our combin-
ing these two outcomes in the main analyses. This is
supported by the similarity of the point estimates for each
outcome.
We deﬁned our population as women without a clinical
diagnosis of diabetes and in whom fasting glucose levels were
less than 7 mmol/l, the current threshold for fasting glucose
used to indicate diabetes. Had we been able to perform oral
glucose tolerance tests on these women at baseline it is
possible that some additional women would have also been
excluded on the basis of elevated 2 h postload glucose. Our
results are appropriately interpreted as suggesting that
amongst older women with fasting glucose levels below 7
mmol/l fasting, insulin is a better predictor of future
cardiovascular risk than fasting glucose or glycated haemo-
globin.
Type 2 diabetes occurs when insulin resistance is combined
with pancreatic b-cell dysfunction and hyperglycaemia
results. There is debate about whether chronic hyperglycae-
mia in patients with diabetes is related to macrovascular
complications, including CHD and stroke [33,34]. If chronic
hyperglycaemia is important in the aetiology of CHD and
stroke in individuals with type 2 diabetes, then it seems likely
that his association would extend to those with high levels of
fasting glucose and HbA1c (indicators of hyperglycaemia) in
the nondiabetic population, but we found no such associa-
tions here. Thus, our ﬁndings suggest that insulin resistance
may be the most important mechanism linking type 2
diabetes to CHD, and possibly stroke, in older women.
However, this interpretation would require testing in large
studies with oral glucose tolerance tests and insulin resistance
measured by euglycaemic clamp studies, which are unlikely to
be conducted for logistic reasons. Alternatively, as genomics
expands it is likely that ﬁnely mapped genetic variants that
affect insulin resistance but not hyperglycaemia and vice
versa will be identiﬁed and robustly replicated. Once they are,
such variants could be used as instrumental variables to
determine the independent causal effects of insulin resistance
and hyperglycaemia on cardiovascular disease risk [35]. If
such studies conﬁrm our ﬁndings, then from a public health
point of view, interventions (both lifestyle and therapeutic)
aimed at preventing insulin resistance might be more
important than those aimed at preventing chronic hyper-
glycaemia. Understanding the relative contributions of
insulin resistance and insulin secretion to the major
consequences of type 2 diabetes, such as the development
of CHD and stroke, is important for developing better-
targeted therapeutics.
There is much debate about how best to identify
individuals at high risk of CHD in clinical practice so that
preventive interventions (changes in lifestyle and therapeu-
tics) can be appropriately targeted to those at most risk
[36,37]. It is now acknowledged that the Framingham
equation varies in its ability to accurately determine risk in
different populations determined by gender, age, and
ethnicity [36,37]. There are also calls for improving predic-
tion in all populations by including a greater number of
(novel) CVD risk factors, though the best methods for
assessing the additional predictive value of new variables is
unclear [38,39]. Our ﬁndings suggest that including fasting
insulin, but not fasting glucose or HbA1c, in CHD risk
assessment of older women might improve prediction in
clinical practice.
Our ﬁndings indicate that amongst older women without
diabetes and with fasting glucose levels in the normal range,
fasting insulin is a stronger predictor of CHD and stroke risk
than are fasting glucose or HbA1c.
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Background. Narrowing of the vessels that take blood to the heart and
brain is a common form of cardiovascular disease—i.e., a disorder of the
heart and blood vessels. It is a major cause of illness and death. By
starving the heart and brain of oxygen, this condition causes coronary
heart disease (CHD; heart problems such as angina and heart attacks)
and strokes. A major risk factor for CHD and strokes is diabetes, a
common chronic disease characterized by high levels of sugar (glucose)
in the blood. In people who don’t have diabetes, the hormone insulin
controls blood-sugar levels. Insulin, which is released by the pancreas
after eating, ‘‘instructs’’ insulin-responsive muscle and fat cells to absorb
the glucose (released from food) from the bloodstream. In the very early
stages of type 2 diabetes (the commonest type of diabetes, also called
‘‘adult onset’’ or ‘‘noninsulin-dependent’’ diabetes’’), muscle and fat
cells become unresponsive to insulin, so blood-sugar levels increase. This
is called ‘‘insulin resistance.’’ The pancreas responds by making more
insulin. As a result, people with insulin resistance have high blood levels
of both insulin (hyperinsulinemia) and glucose (hyperglycemia). Even-
tually, the insulin-producing cells in the pancreas start to malfunction,
insulin secretion decreases, and type 2 diabetes is the result.
Why Was This Study Done? It is not yet clear whether it is insulin
resistance or reduced insulin secretion that is responsible for the
association between diabetes and cardiovascular disease. Physicians
would like to know this information to help them to prevent CHD and
strokes in their patients. There is evidence that variations in fasting
glucose levels (blood glucose measured more than 8 h after eating),
which provide an indication of how well pancreatic cells are producing
insulin, and in fasting insulin levels, which provide an indication of insulin
resistance, determine cardiovascular disease risk among people without
type 2 diabetes, but the relative importance of these risk factors is
unclear. In this study, the researchers have investigated whether markers
of insulin resistance (fasting hyperinsulinemia) and of altered insulin
secretion (fasting hyperglycemia, and increased glycated hemoglobin,
which indicates how much sugar has been in the blood over the past few
months) are associated with CHD and strokes in elderly women without
diabetes. Their aim is to gain new insights into how diabetes affects
cardiovascular disease risk.
What Did the Researchers Do and Find? The researchers measured
glucose, insulin, and glycated hemoglobulin in fasting blood samples
taken from about 3,000 women aged 60–79 y when they enrolled in the
British Women’s Heart and Health Study. None of the women had CHD at
enrollment, none had had a stroke, none had diagnosed diabetes, and all
had a fasting blood glucose below 7 mmol/l (a higher reading indicates
diabetes). After monitoring the women for nearly 5 y for CHD and
strokes, the researchers looked for statistical associations between the
occurrence of cardiovascular disease and markers of insulin resistance
and reduced insulin secretion. They found that fasting insulin levels, but
not fasting glucose or glycated hemoglobin levels, were associated with
CHD and stroke, even after allowing for other factors that affect
cardiovascular disease risk such as smoking and physical activity. In other
words, raised fasting insulin levels increased the women’s risk of
developing cardiovascular disease.
What Do These Findings Mean? These results indicate that in elderly
women without diabetes, fasting insulin (a marker of insulin resistance) is
a better predictor of future cardiovascular disease risk than fasting
glucose or glycated hemoglobin (markers of reduced insulin secretion).
This suggests that insulin resistance might be the main mechanism
linking type 2 diabetes to CHD and stroke in elderly women. (Elderly
women are known to run a high risk of developing these conditions, but
they have been relatively neglected in previous studies of the risk factors
for cardiovascular disease.) However, because relatively few women
developed CHD during the study and even fewer had a stroke, this
conclusion needs confirming in larger studies, preferably ones that
include more rigorous tests of insulin resistance and secretion and also
include women from more ethnic backgrounds than this study did. If the
association between fasting insulin levels and cardiovascular disease risk
is confirmed, therapeutic interventions or lifestyle interventions (for
example, increased physical activity or weight loss) that prevent or
reverse insulin resistance might reduce cardiovascular disease risk better
than interventions that prevent chronic hyperglycemia.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040263.
  MedlinePlus encyclopedia page on coronary heart disease, stroke, and
diabetes (in English and Spanish)
  Information for patients and caregivers from the US National Diabetes
Information Clearinghouse on diabetes, including information on
insulin resistance and on diabetes, heart disease, and stroke
  Information on the British Women’s Heart and Health Study
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